Monosomy 17 in potentially curable HER2 -amplified breast cancer: Prognostic and predictive impact
Breast Cancer Research and Treatment Oct 12, 2017
Page DB, et al. - This work aimed to retrospectively identify HER2-amplified, stage IÂIII breast cancers with monosomy of chromosome 17 (m17) and characterize the impact of trastuzumab treatment. In this study, patients with HER2-amplified m17 cancers treated with trastuzumab indicated outcomes comparable to patients from the large phase III adjuvant trastuzumab trials who were HER2-positive. Findings thereby supported the critical role of HER2-directed therapy in this patient population.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries